Luigi Dogliotti
About
In The Last Decade
Luigi Dogliotti
198 papers receiving 10.9k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Surgery 5.0k
- Oncology 5.0k
- Pulmonary and Respiratory Medicine 2.5k
- Cancer Research 2.2k
- Molecular Biology 1.9k
Countries citing papers authored by Luigi Dogliotti
This map shows the geographic impact of Luigi Dogliotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Dogliotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Dogliotti more than expected).
Fields of papers citing papers by Luigi Dogliotti
This network shows the impact of papers produced by Luigi Dogliotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Dogliotti. The network helps show where Luigi Dogliotti may publish in the future.
Co-authorship network of co-authors of Luigi Dogliotti
This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Dogliotti. A scholar is included among the top collaborators of Luigi Dogliotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Dogliotti. Luigi Dogliotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 19 | |
| 2 | 57 | |
| 3 | 210 | |
| 4 | 5 | |
| 5 | 49 | |
| 6 | 129 | |
| 7 | 12 | |
| 8 | Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients | 6 |
| 9 | 8 | |
| 10 | Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. | 41 |
| 11 | 16 | |
| 12 | 51 | |
| 13 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study breakdown → | 1678 |
| 14 | p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. | 103 |
| 15 | 105 | |
| 16 | 93 | |
| 17 | 41 | |
| 18 | 107 | |
| 19 | Melatonin relationship to human tumors | 4 |
| 20 | Electrolytes and dehydroepiandrosterone sulfate in cyst fluid identify subgroups of patients with gross cystic disease of the breast | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.